{"name":"TR Therapeutics","slug":"tr-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"TR987 0.1% gel + Standard of Care","genericName":"TR987 0.1% gel + Standard of Care","slug":"tr987-0-1-gel-standard-of-care","indication":"Treatment of mild to moderate acne","status":"phase_3"}]}],"pipeline":[{"name":"TR987 0.1% gel + Standard of Care","genericName":"TR987 0.1% gel + Standard of Care","slug":"tr987-0-1-gel-standard-of-care","phase":"phase_3","mechanism":"TR987 0.1% gel works by targeting the existing mechanism of standard of care to enhance its effects.","indications":["Treatment of mild to moderate acne"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9hbGtaY1QwYUR4QlpkSHZYeUZPTXE1Zl82em1HbGtEYVB3Q2RRQ2g1bHBCTWY0OHFwZmxHeUpxdUpFOU5OYUU1b1RNdTlGTUtXcF9YLU9OOXp3cVUyaER5Y2dXV1dPMTJPbzBxeFNn0gFyQVVfeXFMTzF4eHpVOVVoU3Z4OVVkTnAtbzEyWFUzZE5GRjVlTThwZmpSTjQzQ3pIMGQ4dHJxTGZ1TWN4ZG9IdnNNSW14ZzJUY2hNOVZ3T21xbUs1RTV2YVBGem1VcjNINkdUazFhVVUxNXNNdnZ4UVZR?oc=5","date":"2026-03-24","type":"pipeline","source":"koreabiomed.com","summary":"Daewoong teams with TR to supply digital spirometers as Korea expands lung screening - koreabiomed.com","headline":"Daewoong teams with TR to supply digital spirometers as Korea expands lung screening","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxOQ3A5YnpvUWRhTjU3UEFsOW5UeHl6a1o5Ny0yNmxYWHpPYndGa0VmQWVNY2ZZQ2I5cngwTHQ1VE0wX0VuaG1pdG8xdlY0c1FEVzNkX05HenJpOHNkdFlOSjBmdlItX3Q1aDJtcFp2WGJVeXR1c0xoZWJUcHJ5OGFqQ1VHZ215RUZhV1VfajE2Y2RjZ3BxMEk2OGVoYzZtSVVzUXctWHprX085ekRWaGd5R3JzQnFhWXNPa1NxUXphUHN2XzZN?oc=5","date":"2026-01-29","type":"regulatory","source":"VisionMonday.com","summary":"Glaukos Receives FDA Approval of NDA Supplement for Re-Administration of iDose TR - VisionMonday.com","headline":"Glaukos Receives FDA Approval of NDA Supplement for Re-Administration of iDose TR","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxQdzVoOVFucDFHQnJEMk5hZ2ZZUVJqTkNJazBwSHFxSjB1V0F0LXFoY2Q0bmtPZ3V4Z282dFBfNEdTdm5ROGdsOThoWWFBN0VDSVVsdjVXY0kyZXMwNncwcmt3WmdJQUZPVFhOcmlfc05GRVg5ZnFreUxwbW5jZkFWeTNYMURDYWpSQXV4Szk3andrMk5mRHVhV3VXQnJpdHRNRzRrVVdXeXJIR2xtMVpscVRPSUhfdHdrZG51NElsazc1QjJJdTFZMmd1SHpKNXVJbmJUamJGdGVtM21TODU2aVItWkdsUQ?oc=5","date":"2026-01-28","type":"regulatory","source":"Business Wire","summary":"Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR - Business Wire","headline":"Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxQVXpKSHdEOUhsOUNrWkFmT1lCLTd1T2RFQmRWakZfYlJRVTg5RWs5OS1md2s1YkxMbFhaMTZ0RFV4dExRN1J3X0hBdjBOV2YzQ2NueWpac0RjR3hLaU1ZQnJVSURFdWVYbkFYY05nVXdiUVY1MjRRTEdPTDE1YWJtQlNGQnFPQQ?oc=5","date":"2026-01-28","type":"regulatory","source":"Drug Delivery Business","summary":"Glaukos gets FDA nod for iDose TR re-administration - Drug Delivery Business","headline":"Glaukos gets FDA nod for iDose TR re-administration","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZEFVX3lxTE5OdmtXd1pzMmY1X0hUTWU5TU50X2dYYUZGWWw5NjVuV3VOVl91RHd5QnM1ZlJpZE1TODFydFBpdEpvZ0VyekRTNnNsbEpZbllQdDdCSEN1bENianFFbm9FYW9FOWM?oc=5","date":"2026-01-24","type":"pipeline","source":"Verywell Mind","summary":"Can the Diagnostic Manual for Mental Health Do More Harm Than Good? - Verywell Mind","headline":"Can the Diagnostic Manual for Mental Health Do More Harm Than Good?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxPQzRhdHU0TWJ4cVZ5MWVTRE42MXNpdC0wRWhRbTg3djhHOXBaV2RzcDZGdFJ4UWNfSXFGYnpiQ0ZTbzZLZTV2QUNjdzg2dm1GTjdqSm9MM1dtUVZZdGplQ2hKekFpNEdEbDJWcm8xOGFTY1BFUW9zT214YmFPaVdwbVVqQTJNbU9tcGpNb3lVN0ZnNXpPZnZ6MDdfb2p1VGRFdkZPdVcyODd6LUR0WmdEMW03V2RtMVEtYWc?oc=5","date":"2026-01-12","type":"pipeline","source":"GuruFocus","summary":"GSK Collaborates with Summit Therapeutics on Cancer Treatment Tr - GuruFocus","headline":"GSK Collaborates with Summit Therapeutics on Cancer Treatment Tr","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE9rM1Qwb3pnWEludFNzaENOQmlUWWVnbkJQRHdxX3lXMXJwcWVOQldUUDVJUW9UdXhDUFRvVllEVHpnUklzMGhxYm5Dc3VhQmFRVXJGdmk1MzM0clNBbWNuc0RqaVRvYldCb0pyOXBBVUxkUQ?oc=5","date":"2025-12-02","type":"trial","source":"Miami Herald","summary":"GEN Announces New Positive Phase 1 Trial Data of the Investigational Drug SUL-238 for Alzheimer's and Other Neurodegenerative Diseases - Miami Herald","headline":"GEN Announces New Positive Phase 1 Trial Data of the Investigational Drug SUL-238 for Alzheimer's and Other Neurodegener","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTE9EVTRmcTZGMDJKNmhmLUItYy1EN3JZVFozX2RPUXlhX1RTS28xUmtUdkpVVXlmSTZLNmp1XzJGMTlRNFdfWmhlOFJtUm5JU0RMVUl4ajZWZmcwajZBMUY3d1dtS0tJM28?oc=5","date":"2025-11-13","type":"pipeline","source":"Binance","summary":"From Pharmaceuticals to Cryptocurrency: Cypherpunk Technologies and the Bold Decision to Bet Big on Privacy - Binance","headline":"From Pharmaceuticals to Cryptocurrency: Cypherpunk Technologies and the Bold Decision to Bet Big on Privacy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxObkUwTk5YdXJYd3UyMEREMkN6OEhubTlPMHdlVTRIZnpGOS0tai1Mb2tnaXlnbHNPZ2ZFSWlOWTA4d2UtSGxfVURTZ1U3eENONWszOURXVWhmeGFFZG5raGdNZ0N4c2lzdHBSZHJ3a05KOGVURGpreUF2YjdRaldhMDZfb1B4c2xGU25VWFhxZ0FlWmxvcEc5MnhR?oc=5","date":"2025-05-27","type":"trial","source":"Clinical Trials Arena","summary":"Patient dies in Rocket’s Phase II Danon disease gene therapy trial - Clinical Trials Arena","headline":"Patient dies in Rocket’s Phase II Danon disease gene therapy trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxQcVhzTkw4MUhOSl9NSWUtMk1HTnlHZE9PaDB6SURtNXk4SmtnUTIwUmtPLXBqeGZPNEtQdVNzdlUxWi1TWGJpRThBMzZjSzNMaUV1WnRDNnllZk9PY3l1anNnbUljZnZvMWI0NVE5endDTDB5cmtaYW9QWEtaZndCVV9tV2N6OUR5Q2Z0YXFxT1AtMkVxazBKNzFIVkdnUlVRQ0xuMDZrTXBJMHFOeEJLRjFINlhGb1VrVnc?oc=5","date":"2025-04-28","type":"deal","source":"Anadolu Ajansı","summary":"German pharma firm Merck to acquire US-based SpringWorks Therapeutics for $3.9B - Anadolu Ajansı","headline":"German pharma firm Merck to acquire US-based SpringWorks Therapeutics for $3.9B - Anadolu Ajansı","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE52a0tCdzRXOWo2VENrY3RtOVRLa0tFTk5hNG55WktGSzh2bllGZ0QtMDhmWFhPZVZrbUxDS0Jaa3hCdU1rMGRvckxRaG1TYktVaUtMTm5BQmFDRnVsdTBYY0wzZDEzOVlj?oc=5","date":"2025-04-18","type":"regulatory","source":"Wiley Online Library","summary":"Editorial: Carvedilol Remains the First-Line Treatment of Portal Hypertension After the CALIBRE Trial - Wiley Online Library","headline":"Editorial: Carvedilol Remains the First-Line Treatment of Portal Hypertension After the CALIBRE Trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTFBkejMydnlua3ktbk9OQzhBTlRFY0VMTlNsR3lRVzRRbnA4TVpPRFpnbUpXZXA3dXVnZzUtN2lERlJuX1ROZXBWLUFScWFJWWhVSmlETFU1VTdTbm4ycm9HSXJiclNramRuc3pJZzQ0WVNCYWJTX3R2YW93?oc=5","date":"2024-11-14","type":"pipeline","source":"Timmerman Report","summary":"Save the Date: TR 10th Anniversary - Timmerman Report","headline":"Save the Date: TR 10th Anniversary","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}